Clinical Scorecard: Can an antibody aid neuropsychiatric SLE diagnosis?
At a Glance
| Category | Detail |
|---|---|
| Condition | Neuropsychiatric systemic lupus erythematosus (NPSLE) |
| Key Mechanisms | Cerebrospinal fluid antisuprabasin antibody |
| Target Population | Patients with systemic lupus erythematosus presenting with neuropsychiatric symptoms |
| Care Setting | Emergency department |
Key Highlights
- Cerebrospinal fluid antisuprabasin antibody showed greater diagnostic accuracy for NPSLE compared to other tests.
- The study included 148 patients with SLE who underwent lumbar puncture.
- CSF antisuprabasin antibody had 81% sensitivity and 74% specificity at an optimal cutoff of 76.36 ng/mL.
- A combined model of CSF antisuprabasin antibody, CSF white blood cell count, and serum antiribosomal P antibody yielded an area under the curve of 0.892.
- The study calls for multicenter longitudinal studies to validate findings.
Guideline-Based Recommendations
Diagnosis
- Use cerebrospinal fluid antisuprabasin antibody for identifying NPSLE among SLE patients with neuropsychiatric symptoms.
Management
Monitoring & Follow-up
Risks
- Single-center design and limited cohort size may restrict generalizability.
Patient & Prescribing Data
Patients with systemic lupus erythematosus and neuropsychiatric symptoms.
The posttreatment trajectory of CSF antisuprabasin antibody remains unknown.
Clinical Best Practices
- Consider CSF antisuprabasin antibody testing in patients with SLE presenting with neuropsychiatric symptoms.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
